Markt geschlossen -
Andere Börsenplätze
|
% 5 Tage | % 1. Jan. | ||
1.06 USD | -4.50% | +6.00% | +0.95% |
01.04. | Quince Therapeutics, Inc. meldet Ergebnis für das am 31. Dezember 2023 endende Geschäftsjahr | CI |
26.03. | Transcript : Quince Therapeutics, Inc. - Special Call |
Kurzporträt
Mitarbeiterzahl: 32
Manager
Manager | Titel | Alter | Seit |
---|---|---|---|
Dirk Thye
CEO | Chief Executive Officer | 54 | 19.05.22 |
Brendan Hannah
DFI | Director of Finance/CFO | 39 | 01.05.22 |
Charles Ryan
PSD | President | 60 | 01.09.23 |
Maureen M. Roden
CTO | Chief Tech/Sci/R&D Officer | - | 01.06.22 |
Stacy Roughan
IRC | Investor Relations Contact | - | - |
Gary Ward
PRN | Corporate Officer/Principal | - | 01.08.22 |
Human Resources Officer | - | - |
Aufsichtsräte
Aufsichtsräte | Titel | Alter | Seit |
---|---|---|---|
Una Ryan
BRD | Director/Board Member | 82 | 01.03.18 |
Luca Benatti
BRD | Director/Board Member | 63 | 23.10.23 |
Dirk Thye
CEO | Chief Executive Officer | 54 | 19.05.22 |
David Lamond
CHM | Chairman | 49 | 01.12.15 |
Rajiv Patni
BRD | Director/Board Member | 55 | 15.02. |
Director/Board Member | 56 | 01.03.19 | |
Director/Board Member | 61 | 01.12.15 | |
June Bray
BRD | Director/Board Member | 70 | 09.06.22 |
Anteilsklasse
Vote | Menge | Streubesitz | Konzerneigene Aktien | Total Float | |
---|---|---|---|---|---|
Aktie A | 1 | 43 215 233 | 35 841 506 ( 82,94 %) | 0 | 82,94 % |
Unternehmenskontakt
Quince Therapeutics, Inc.
611 Gateway Boulevard Suite 273
94080, South San Francisco
+
http://quincetx.comSektor
% 1. Jan. | Kap. | |
---|---|---|
+0.95% | 47.97 Mio. | |
+4.09% | 43.43 Mrd. | |
+47.81% | 41.69 Mrd. | |
+9.45% | 41.31 Mrd. | |
-10.92% | 27.14 Mrd. | |
+9.32% | 25.28 Mrd. | |
-24.87% | 18.47 Mrd. | |
+29.70% | 12.59 Mrd. | |
+1.28% | 12.33 Mrd. | |
+7.78% | 11.03 Mrd. |
- Börse
- Aktien
- A2PHHD Aktie
- Unternehmen Quince Therapeutics, Inc.